Quantum-Si (QSI) Projected to Post Quarterly Earnings on Tuesday

Quantum-Si (NASDAQ:QSI) is anticipated to post its Q4 2025 results after the market closes on Tuesday, March 3rd. Analysts expect Quantum-Si to post earnings of ($0.14) per share and revenue of $0.7620 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 4:30 PM ET.

Quantum-Si Stock Performance

NASDAQ QSI opened at $0.96 on Monday. The stock’s fifty day moving average is $1.13 and its two-hundred day moving average is $1.38. The firm has a market capitalization of $206.09 million, a P/E ratio of -1.43 and a beta of 3.00. Quantum-Si has a fifty-two week low of $0.89 and a fifty-two week high of $3.10.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on QSI shares. Canaccord Genuity Group dropped their price objective on shares of Quantum-Si from $2.00 to $1.50 and set a “hold” rating for the company in a report on Monday, December 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Quantum-Si in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $3.55.

Insiders Place Their Bets

In other Quantum-Si news, insider John S. Vieceli sold 21,927 shares of Quantum-Si stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $1.28, for a total value of $28,066.56. Following the completion of the transaction, the insider directly owned 800,973 shares of the company’s stock, valued at $1,025,245.44. The trade was a 2.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jeffrey Alan Hawkins sold 23,707 shares of the business’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $1.28, for a total transaction of $30,344.96. Following the sale, the chief executive officer owned 2,578,018 shares in the company, valued at $3,299,863.04. This trade represents a 0.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 54,261 shares of company stock valued at $69,454 over the last ninety days. Insiders own 22.95% of the company’s stock.

Hedge Funds Weigh In On Quantum-Si

A number of institutional investors and hedge funds have recently made changes to their positions in QSI. JPMorgan Chase & Co. increased its stake in shares of Quantum-Si by 15.6% during the second quarter. JPMorgan Chase & Co. now owns 66,656 shares of the company’s stock worth $131,000 after buying an additional 9,005 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Quantum-Si by 27.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 49,082 shares of the company’s stock valued at $96,000 after purchasing an additional 10,564 shares during the last quarter. Prudential Financial Inc. purchased a new stake in shares of Quantum-Si in the 2nd quarter valued at approximately $25,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Quantum-Si by 23.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,552 shares of the company’s stock valued at $85,000 after purchasing an additional 13,546 shares in the last quarter. Finally, Cerity Partners LLC purchased a new stake in shares of Quantum-Si during the 2nd quarter worth $29,000. 39.90% of the stock is owned by institutional investors and hedge funds.

Quantum-Si Company Profile

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.